scispace - formally typeset
J

Jerome Tamburini

Researcher at University of Paris

Publications -  151
Citations -  11002

Jerome Tamburini is an academic researcher from University of Paris. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 38, co-authored 135 publications receiving 9567 citations. Previous affiliations of Jerome Tamburini include Paris Descartes University & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Nathalie Jacque, +28 more
- 10 Sep 2015 - 
TL;DR: It is shown that glutamine levels control mitochondrial oxidative phosphorylation (OXPHOS) in acute myeloid leukemia (AML) cells and targeting glutamine addiction via GLS1 inhibition offers a potential novel therapeutic strategy for AML.
Journal ArticleDOI

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

Elizabeth C. Townsend, +98 more
- 11 Apr 2016 - 
TL;DR: It is demonstrated that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.
Journal ArticleDOI

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways

Jerome Tamburini, +14 more
- 01 Jan 2008 - 
TL;DR: The results suggest that dual inhibition of the mTORC1 complex and the IGF-1/IGF-1R/PI3K/Akt pathway in AML may enhance the efficacy of mTOR inhibitors in treatment of this disease.
Journal ArticleDOI

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

Sophie Park, +9 more
- 01 May 2010 - 
TL;DR: The results open the way for the design of direct inhibitors of protein synthesis as novel acute myeloid leukemia therapies and also for the development of second generation mTOR inhibitors (the TORKinhibs).